2497. Package #240.1 (ANA. Systemic lupus erythematosus (SLE), quantitative determination, IgG antibodies)

To date, the diagnosis of systemic lupus erythematosus (SLE) is most commonly guided by the 2012 classification criteria of the American College of Rheumatology (ACR). They include clinical features, blood test findings, and immunological abnormalities (11 criteria in total). If 4 or more ACR criteria are identified in a patient, a diagnosis of SLE is considered possible.

Test panel No. 240.1 is designed to detect autoantibodies in patients (primarily women of reproductive age, 20–40 years old) who present with characteristic symptoms such as weakness and fatigue, low-grade fever or fever, and weight loss.

The following antibody types are of particular clinical significance in SLE:

• dsDNA (specificity for SLE can reach 100%);
• Sm DP-S;
• SS-A/Ro;
• Rib-P;
• PCNA;
• U1-RNP.

Systemic lupus erythematosus (SLE) is a chronic multisystem inflammatory disease of autoimmune etiology that predominantly affects young women. The disease most commonly manifests as arthralgia and arthritis, Raynaud’s syndrome, characteristic skin rashes (e.g., a butterfly-shaped rash), pleuritis or pericarditis, renal or central nervous system involvement, and hematologic cytopenias.

The diagnosis is based on clinical manifestations and the results of serological tests. According to the ACR criteria, the presence of antinuclear antibodies (ANA) is one of the diagnostic criteria and is assigned 1 point. A high titer (above 1:160) is more specific for SLE.

• For the diagnosis of systemic lupus erythematosus (SLE) in patients with fever of unknown origin, arthritis, or skin rashes.
• For monitoring the course of SLE and assessing treatment efficacy.
• For the differential diagnosis of various autoimmune disorders.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: